Trial Profile
Efficacy of Aflibercept (Eylea) on Choroidal Neovascularization (Type 3)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Mar 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- Acronyms ATTRACT
- 07 Mar 2019 Status changed from active, no longer recruiting to completed.
- 03 Apr 2018 Planned End Date changed from 1 Nov 2017 to 1 Nov 2019.
- 03 Apr 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2019.